In June 2017, the Molecular Evidence Development Consortium (MED-C) rebranded as Cure-One. See the press release here and the new website here. Dane Dickson MD remains founder and CEO (Linked In here).
Cure-One announced a registry-based partnership Guardant Health in June, here.
Press release quoted below the break. In related news, CLINVAR recently endorsed a set of major national genomics labs that follow recommended data-sharing guidelines (here).
WASSO, Okla., June 2, 2017 /PRNewswire
The Molecular Evidence Development Consortium (MED-C), a non-profit organization seeking to advance precision medicine, announced today it is changing its corporate name to Cure-One™. The name change reflects the company's unwavering commitment to patients.
"The MED-C name described our intentions—bringing people together to collect better evidence to support precision medicine. As we have evolved, it's now time for us to focus on the ultimate goal of collecting this data in an effort to find cures for diseases where there currently are none. The goal is to cure people one by one, thus the name Cure-One," said Chief Executive Officer and Founder of Cure-One, Dane J. Dickson MD. [Linked In here.]
Cure-One is focused on high-quality, standardized data collection to aid in the research to cure persistent diseases. The company has created the N1 Registry™, an independent registry that connects the dots between high quality, standardized molecular testing and associated clinical outcomes for cancer patients. The resulting database will allow the healthcare's most influential market segments to obtain direct access to richly detailed genetic-level testing and tie it to associated clinical outcomes. The registry is built to motivate, mediate, and deliver more unified healthcare, which will ultimately close disconnects and catalyze precision medicine to deliver personalized cures.
"We want to build a sustainable database—one that is standardized and accessible for everyone, so all will benefit. The insurer will receive critical information regarding quality, patients will have access to better diagnostics and more effective treatments, physicians will be able to provide better options for their patients, and pharmaceutical companies, researchers and laboratories will benefit from the rapid advancement of precision medicine.We are developing an essential, yet missing, cornerstone in precision medicine with our N1 Registry," Dickson said.
Cure-One is an independent, non-profit organization dedicated to advancing precision medicine by helping patients access leading-edge genetic-level testing and treatment. The company seeks to make critical laboratory data readily accessible to physicians, researchers, insurance and pharmaceutical companies to advance disease technologies and develop treatments to improve the quality of care in patients with cancer and chronic diseases. Cure-One strives to bring these key medical groups together to build a world where it is never too late for a cure.
For more information, please visit www.cure-one.org.